Esco Aster vs Evox Therapeutics: CDMO Comparison

Side-by-side comparison of Esco Aster and Evox Therapeutics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Singapore, SG
Signal Score
63/100
Quality (FDA + GMP)
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
Modalities
Cell Therapy, Exosome
Oxford, UK
Signal Score
58/100
Quality (FDA + GMP)
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
Modalities
Exosome

What to evaluate for Exosome programs

Both Esco Aster and Evox Therapeutics qualify as Exosome CDMOs. When choosing between them for Exosome programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

Cell source & scale

Confirm the producer cell source and whether culture is suspension-adapted for the volumes EV yields demand.

Isolation & purification

Isolation method (tangential-flow filtration, chromatography) drives yield, purity, and scalability. Ask how it performs at your target scale.

Characterization & potency

EV characterization (particle count, size, cargo, identity) and potency assays are still maturing — look for established, qualified methods.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

See all Exosome CDMOs ranked by Signal Score →

Frequently asked: Esco Aster vs Evox Therapeutics

Which is better for Exosome manufacturing — Esco Aster or Evox Therapeutics?

Both Esco Aster and Evox Therapeutics are tagged as Exosome CDMOs in our directory, so both are credible options for Exosome programs. The most important differentiator for Exosome selection is typically cell source & scale: Confirm the producer cell source and whether culture is suspension-adapted for the volumes EV yields demand. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

Esco Aster carries a Signal Score of 63/100 and Evox Therapeutics carries 58/100 — a small lead for Esco Aster. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Esco Aster and Evox Therapeutics for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.